v3.26.1
Revenue and government financing for research expenditures (Tables)
 12 Months Ended
Dec. 31, 2025
Disclosure of disaggregation of revenue from contracts with customers [abstract]  
Disclosure of revenue from collaboration and licensing agreements
Year ended December 31,
(in thousands of euro)
2023(1)
2024
2025
Proceeds from collaboration and licensing agreements 50,725 10,505 620 
of which monalizumab agreement - AstraZeneca9,499 4,404 220 
of which IPH5201 agreement - AstraZeneca— — — 
of which preclinical molecules agreement - AstraZeneca— — — 
of which Sanofi agreement 20162,000 4,000 — 
of which Sanofi agreement 2022 - ANKET IPH62 - Recognition of license initial payment and income related to the completion of work in line with the joint research program18,873401400
of which Sanofi agreement 2022 - ANKET IPH67 -Recognition of license initial payment and income related to the progress of related research program15,8001,700—
of which Takeda agreement 20234,553—
Invoicing of research and development costs (IPH5201) 1,165 2,060 1,666 
Others11 56 501 
Revenue from collaboration and licensing agreements51,901 12,622 2,787 
Disclosure of changes in deferred revenue and collaboration liabilities
Change in monalizumab deferred revenue (in thousands of euro):
As of December 31, 202214,481 
Revenue for the 2023 financial year
(9,499)
Transfer from collaboration liabilities173 
As of December 31, 20235,156 
Revenue for the 2024 financial year
(4,404)
Transfer from collaboration liabilities(536)
As of December 31, 2024215 
Revenue for the 2025 financial year
(220)
Transfer from collaboration liabilities5
As of December 31, 2025—
Change in monalizumab collaboration liablities (in thousands of euro):
Current
Non-Current
Total
As of December 31, 202210,223 52,988 63,211 
Additions (2)7,785 (7,958)(173)
Repayment cost to AZ(8,423)— (8,423)
Fx impact
(1,938)— (1,938)
As of December 31, 2023 (3)7,647 45,030 52,677 
Additions4,303 (3,902)401 
Repayment cost to AZ(7,772)— (7,772)
Fx impact
3,265 — 3,265 
As of December 31, 2024 (4)7,443 41,128 48,571 
Additions9,521 (9,380)141 
Repayment cost to AZ(4,792)— (4,792)
Fx impact
(5,671)— (5,671)
As of December 31, 2025 (5)6,501 31,748 38,249 
Change in deferred revenue relating to the 2022 research collaboration and licensing agreement :
As of December 31, 2022— 
Additions8,200 
Deductions(2,874)
As of December 31, 20235,327 
Additions— 
Deductions(2,101)
As of December 31, 20243,226 
Additions—
Deductions(400)
As of December 31, 20252,826
Disclosure of variance of deferred revenue
The main variance of the global deferred revenue is presented in the following schedule:

(in thousands of euro)December 31, 2022Recognition in P&LProceedsTransfer from collaboration liabilitiesDecember 31, 2023
Monalizumab14,481 (9,499)— 173 5,155 
Sanofi services— (374)3,200 — 2,826 
Sanofi options
—(2,500)5,000—2,500
Total 14,481 (12,373)8,200 173 10,483 
(1)Of which €5,865 thousand of current deferred revenue and €4,618 thousand of non-current deferred revenue.

(in thousands of euro)December 31, 2023Recognition in P&LProceedsTransfer from collaboration liabilitiesDecember 31, 2024
Monalizumab5,155 (4,404)— (536)215 
Sanofi options
2,500 — — — 2,500 
Sanofi services
2,826 (2,100)— — 726 
Others—————
Total 10,483 (6,504)— (536)3,441 
(2)
(2) Of which €616 thousand of current deferred revenue and €2,825 thousand of non-current deferred revenue.

(in thousands of euro)December 31, 2024Recognition in P&LProceeds and other increaseTransfer from collaboration liabilitiesDecember 31, 2025
Monalizumab215 (220)— 5 — 
Sanofi options2,500 — — — 2,500 
Sanofi services726 (400)— —326 
Total3,441 (620)— 5 2,826 
(3)
(3) Of which €2,825 thousand of current deferred revenue.
Disclosure of government financing for research expenditures
The total amount for government financing for research expenditures recorded as other income in the income statement can be analyzed as follows:
Year ended December 31,
(in thousands of euro)202320242025
Research Tax Credit9,729 7,463 6,186 
Grant and other tax credit (1)— 25 19 
Government financing for research expenditures9,729 7,488 6,205 
(1) As of December 31, 2025, the amount is composed of the research tax credit calculated and recognized for the 2024 financial year for an amount of €6,186 thousand.As a reminder, as of December 31, 2024 and 2023, the amount is mainly composed of the research tax credit calculated and recognized for the 2023 financial year for an amount of € 7,463 thousand and €9,729 thousand.